RespireRx Pharmaceuticals Inc (fka RSPI)

[enemem]

On one hand, the changed financial landscape probably leaves BP's estimate of IP value, and the estimate assigned to the same IP by the microcap biotech that developed it even further apart than before. This is likely to slow things down.

On the other hand, a given burn rate imposes a time-line.

The only thing this has in common with high-stakes poker is the stress. It's a completely different kind of problem.

Coming out of the conference, can you assign an estimate to the upfronts that cor can expect in an eventual RD-only partnership?